Ads
related to: cholesteryl ester vs cetp 2- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- Patient Identification
View a Patient Profile
to Learn More
- Trial Results
See Clinical Data
and Trial
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
1071 n/a Ensembl ENSG00000087237 n/a UniProt P11597 n/a RefSeq (mRNA) NM_000078 NM_001286085 n/a RefSeq (protein) NP_000069 NP_001273014 n/a Location (UCSC) Chr 16: 56.96 – 56.98 Mb n/a PubMed search n/a Wikidata View/Edit Human Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein, is a plasma protein that facilitates the transport of cholesteryl esters and ...
A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP). [1] [2] ...
Cholesteryl ester is transported from high-density lipoproteins (HDLs) to low-density lipoproteins (LDLs) and very low-density lipoproteins (VLDLs) with cholesteryl ester transfer protein (CETP). [5] The decrease in cholesteryl ester can lower HDL and increase LDL, which may be an indicator of cardiovascular problems, as indicated by ...
In humans, probably the most relevant pathway is the indirect one, which is mediated by cholesteryl ester transfer protein (CETP). [2] This protein exchanges triglycerides of VLDL against cholesteryl esters of HDL.
The cholesteryl esters can be transferred, with the help of CETP (cholesterylester transfer protein) in exchange for triglycerides, to ApoB-containing lipoproteins (LDL, VLDL, IDL). These other lipoproteins can be eventually taken up by the liver through their own receptors – an alternate route for liver uptake – or end up transporting the ...
Some people with type 2 diabetes can control their blood glucose through a combination of a healthy diet and increased physical activity, but many rely on medications to reduce blood glucose ...
It converts free cholesterol into cholesteryl ester, a more hydrophobic form of cholesterol. This process sequesters cholesterol ester into the core of a lipoprotein particle, eventually making the newly synthesized HDL spherical and forcing the reaction to become unidirectional since the particles are removed from the surface.
Dalcetrapib [4] (INN, codenamed JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. [ 5 ] [ 6 ] DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease.